Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

206.64 +0.75 (+0.36%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why Revolution Medicines Stock Surged by 11% Today ↗

January 09, 2026

The company might become the latest biotech acquisition story soon.

Via The Motley Fool

Topics Intellectual Property

Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗

January 09, 2026

Via Stocktwits

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗

January 09, 2026

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32...

Via Benzinga

Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles

January 08, 2026

In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗

January 08, 2026

Via Stocktwits

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

Revolution Medicines Stock Soars On Report Of AbbVie Takeover ↗

January 07, 2026

The Wall Street Journal reported on Wednesday, citing people familiar with the matter, that AbbVie is in advanced talks to buy Revolution Medicines, while adding it couldn’t learn how much AbbVie is...

Via Stocktwits

The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens

January 02, 2026

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU

January 01, 2026

As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗

December 10, 2025

Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that.

Via The Motley Fool

Topics Artificial Intelligence

Maplebear, Tower Semiconductor, And Eli Lilly Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 10-Nov. 14): Are the Others in Your Portfolio? ↗

November 16, 2025

Ten large-cap standouts—including Maplebear, Tower Semiconductor, Eli Lilly, On Holding, Albemarle, and key gold/silver miners—rallied last week on strong earnings, upbeat guidance, analyst upgrades,...

Via Benzinga

Revolution Medicines (RVMD) Earnings Transcript ↗

November 05, 2025

Revolution Medicines (RVMD) Earnings Transcript

Via The Motley Fool

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗

October 23, 2025

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Via Benzinga

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday ↗

October 17, 2025

Via Benzinga

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗

October 17, 2025

The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.

Via Investor's Business Daily

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold' ↗

October 17, 2025

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620.

Via Benzinga

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Via Stocktwits

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug ↗

September 11, 2025

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 11, 2025

Via Benzinga

Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 10, 2025

Via Benzinga

This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

August 15, 2025

Via Benzinga

Revolution Medicines Inc (NASDAQ:RVMD) Reports Q2 2025 Earnings Miss, Shares Drop 4.5% After-Hours ↗

August 06, 2025

Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for...

Via Chartmill

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.